

# KOBO BIOTECH LIMITED

(Formerly known as Avon Lifesciences Limited)

Corp. Office : 'H' Wing , 4th Floor, Tex Centre, Off Saki Vihar Road,  
Chandivali, Andheri (E), Mumbai - 400 072, INDIA.  
Tel. : +91-22 4287 1210 • Fax : +91-22-4287 1285

E-mail : info@avonlifesciences.com • Website : www.avonlifesciences.com  
(CIN : L24110TG1993PLC16112)

Asst. General Manager,  
Dept. of Corporate Services.  
Bombay Stock Exchange Limited,  
14th Floor, P.J.Towers, Dalal Street, Fort,  
Mumbai: 400 001

12<sup>th</sup> February, 2021

Dear Sir/ Madam,

Scrip Name: Kobo Biotech Limited, Scrip Code: 531541

**Sub: OUTCOME OF THE BOARD MEETING: Unaudited Financial results for the Quarter and nine months ended 31<sup>st</sup> December, 2020.**

This is to inform you that the Board of Directors of Kobo Biotech Limited at their meeting held today i.e. on Friday, 12<sup>th</sup> February, 2021 inter alia approved the Unaudited Financial Results of the Company for the quarter and nine month ended 31<sup>st</sup> December, 2020 alongwith the limited review report of statutory auditor thereon.

Please find enclosed a copy of the unaudited Financials along with Limited Review report from the Statutory Auditors.

The above-referred meeting was commenced at 3:00 p.m. and concluded at 3:45 p.m.

The above is pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, for your information and record.

Thank you,

For Kobo Biotech Limited

*J.M. Patel*  
Jignesh Patel  
Company Secretary



**KOBO BIOTECH LIMITED**  
CIN: L24110TG1993PLC016112

Regd. Office : Regd. Office : 505, Plot No.193 & 193/1, Chandi Nilayam, Samatha Nagar, Bhagyanagar 3rd Phase, Kukatpally, Hyderabad - 500 085  
Corp. Office : H Wing, 4th Floor, Tex Centre, Off Saki Vihar Road, Chandivali, Andheri (East), Mumbai - 400 072

**Statement of Unaudited Financial Results for the quarter and Nine Month ended 31st December, 2020**

(Amount in INR Lakhs)

Sr. No.	PARTICULARS	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2020	30.09.2020	31.12.2019	31.12.2020	31.12.2019	31.03.2020
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Income from operations	0.00	0.00	0.00	0.00	0.00	0.00
II	Other Income	0.00	0.00	0.00	3.59	3.44	3.44
III	<b>Total Income (I+II)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>3.59</b>	<b>3.44</b>	<b>3.44</b>
IV	<b>Expenditure</b>						
	(a) Cost of raw material consumed	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Employee benefits expense	42.46	46.89	39.72	132.88	131.43	179.63
	(d) Finance Cost	360.07	360.00	365.46	1,084.07	1,085.47	1,447.47
	(e) Depreciation and Amortisation expenses	142.11	142.09	149.03	424.76	443.00	587.82
	(f) Exchange (Gain)/Loss	0.00	0.00	0.00	0.00	0.00	(192.00)
	(g) Other Expenses	29.71	19.85	20.28	66.18	64.59	81.14
	<b>Total Expenses</b>	<b>574.35</b>	<b>568.83</b>	<b>574.49</b>	<b>1,707.89</b>	<b>1,724.49</b>	<b>2,104.06</b>
V	<b>Profit/(Loss) before Exceptional Items and Tax (III-IV)</b>	<b>(574.35)</b>	<b>(568.83)</b>	<b>(574.49)</b>	<b>(1,704.30)</b>	<b>(1,721.05)</b>	<b>(2,100.62)</b>
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	<b>Profit/(Loss) before Tax (V-VI)</b>	<b>(574.35)</b>	<b>(568.83)</b>	<b>(574.49)</b>	<b>(1,704.30)</b>	<b>(1,721.05)</b>	<b>(2,100.62)</b>
VIII	<b>Tax expenses</b>						
	(a) Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
IX	<b>Net Profit/(Loss) after tax (VII-VIII)</b>	<b>(574.35)</b>	<b>(568.83)</b>	<b>(574.49)</b>	<b>(1,704.30)</b>	<b>(1,721.05)</b>	<b>(2,100.62)</b>
X	<b>Other Comprehensive Income</b>						
	(i) Items that will not be reclassified to Profit or Loss	0.00	0.00	0.00	0.00	0.00	0.00
XI	<b>Total Comprehensive Income for the period (IX+X)</b>	<b>(574.35)</b>	<b>(568.83)</b>	<b>(574.49)</b>	<b>(1,704.30)</b>	<b>(1,721.05)</b>	<b>(2,100.62)</b>
XII	Paid-up equity share capital	2,382.50	2,382.50	2,382.50	2,382.50	2,382.50	2,382.50
XIII	Other Equity	-	-	-	-	-	(11,179.59)
XIV	<b>Earnings (Loss) Per Share (Basic and Diluted) (In Rs.)</b>	<b>(2.41)</b>	<b>(2.39)</b>	<b>(2.41)</b>	<b>(7.15)</b>	<b>(7.22)</b>	<b>(8.82)</b>

**Notes :**

1	The above unaudited financial results, have been prepared in accordance with the Indian Accounting Standards (Ind AS), the provisions of the Companies Act, 2013 and guidelines issued by the Securities and Exchange Board of India, and the same have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 12th February 2021
2	The Company operates only in one Business Segment i.e. manufacturing Active Pharmaceutical Ingredients (API)/ Bulk Drugs.
3	The company is presently developing APIs in various therapeutic segments to be soon commercialised at the Solapur site. The company would be approaching the state FDA for relevant licences and permissions for manufacturing the new APIs. The company continues to hold a valid Establishment Inspection Report issued by the USFDA in 2016. The Company is taking appropriate efforts to find a strategic investor and to restart the operational activities at the Solapur Site at the earliest.
4	The number of investor complaints at the beginning and pending at the end of the Quarter were Nil.
5	The figures of previous period / year have been regrouped / rearranged wherever necessary / practicable to conform to current period/year presentation.

By order of the Board  
For KOBO BIOTECH LIMITED



Ajit Kamath  
Director



*CA. Mukesh Mehta*

B. Com. F.C.A.

*CA. Shantilal Jain*

B. Com. F.C.A.

*CA. Prince Kothari*

B. Com. A.C.A.

**N. G. JAIN & CO.**  
**CHARTERED ACCOUNTANTS**

320, Hammersmith Ind. Premises Co-op. Soc. Ltd., Narayan Pathare Marg, Off. Sitladevi Temple Road, Mahim (West)  
Mumbai - 400 016. Office Phone : + 91 22 24440564 / + 91 22 24440716 / 249740716

**Limited Review Report of Un-audited Financial Results of Kobo Biotech Limited**

We have reviewed the accompanying statement of un-audited financial results of Kobo Biotech Limited for the quarter and Nine Month ended 31<sup>st</sup> December 2020 being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors and has been prepared in accordance with the companies (Indian Accounting Standards) Rules, 2015 (Ind AS), Prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of un-audited financial results has not been prepared in accordance with applicable Indian accounting standards (Ind AS) and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N G Jain & Co  
Chartered Accountants

*Prince Kothari*

Prince Kothari  
Partner

Membership No.: 155819  
FRN No.: 103941W



Place: Mumbai

Date: 12/02/2021

UDIN No: 21155819AAAAAU1453